Dr. Paul Schaffer Joins Telix to Drive Innovation in Radiopharma

Telix Pharmaceuticals is pleased to announce the appointment of Dr. Paul Schaffer as Chief Technology Officer (CTO), effective immediately. This newly created role underscores Telix’s commitment to innovation as it continues to advance radiopharmaceutical research and patient care.

Dr. Schaffer joins Telix following the acquisition of ARTMS Inc. in 2024, where he served as CTO for seven years. He also held the position of Director of Life Science at TRIUMF, Canada’s national particle accelerator research centre, since 2012. Widely regarded for his pioneering work in isotope production, Dr. Schaffer played a key role in the development of the ARTMS QUANTM Irradiation System® (QIS®), a groundbreaking technology for large-scale isotope production now part of Telix’s growing portfolio.

As CTO, Dr. Schaffer will lead Telix’s technological strategy across a range of disciplines, including chemistry, physics, artificial intelligence, dosimetry, and data analytics. He will collaborate closely with Telix’s Chief Scientist, Dr. Michael Wheatcroft, to help shape the company’s next wave of innovation in radiopharmaceutical development.

Dr. Schaffer said, “I’m excited to be taking on this role at such a pivotal time for Telix, as the company rapidly advances its mission to transform patient care. Telix has a bold vision for the future, and I look forward to working with this talented team to help bring the next generation of radiotherapeutics to life.”

Dr. Christian Behrenbruch, Managing Director and Group CEO of Telix, commented, “Paul has an outstanding track record in scientific innovation, particularly in the development of advanced isotope production technologies. I’ve had the pleasure of working alongside him for many years and have always been impressed by his intellect, creativity, and deep commitment to advancing the field. We’re thrilled to have him formally join our leadership team.”

Dr. Schaffer’s appointment comes at a time of strong momentum for Telix, as the company continues to lead the way in developing novel radiopharmaceutical solutions for cancer and other serious diseases.